Dr Richard Harbottle
Dr Richard Harbottle is currently an Independent Group Leader of Gene Therapy Research in the section of Molecular Medicine at Deutsches Krebsforschungszentrum (DKFZ). The Cancer Research Centre based in Germany. Previously Richard was at Imperial College London where his key research focused on the development of DNA technologies for gene therapy, with a particular focus on the application of scaffold/matrix attachment region (S/MAR) vectors.
His group utilises state-of-the-art techniques in molecular and cellular biology and bio-imaging with an emphasis in gene delivery to pre-clinical model systems. A particular focus of his group is the development of genetically marked tumour models, which can be used to investigate the molecular mechanisms of tumour formation as well as simplifying the validation of therapeutic intervention.
Richard is a also a founding member of the British Society for Gene Therapy and served as an elected member of its executive board since the inception of the society in 2003 until 2010. He is an active member of the society and currently contributes as a co-opted member of the executive. He is also an active member and participant of the American and European gene therapy societies and the American Association of Cancer Research.
Professor Hilary Calvert
Professor Calvert, who has recently been appointed Director of Cancer Drug Discovery and Development at the UCL Cancer Institute, is internationally known among medical oncologists for his seminal work on chemotherapy and the development of the Calvert formula, which has benefited countless patients around the world.
He has a longstanding interest in developing new drugs for cancer treatment and has been associated with several successful drugs currently used worldwide. These include carboplatin (for ovarian cancer), pemetrexed (for mesothelioma and lung cancer) and inhibitors of poly (ADP- ribose)polymerase (PARP) for familial breast and ovarian cancers. He has previously worked in the Royal Marsden Hospital and the University of Newcastle (as professor of Medical Oncology).
As well as his new appointment as Director of Cancer Drug Discovery and Development at the UCL Cancer Institute, Professor Calvert will also take over as Chair of the New Agents Committee at Cancer Research UK in December 2012. He is a member of the Department of Health’s Gene Therapy Advisory Committee and has recently served on the Health Services and Public Health Research Board at the Medical Research Council. Internationally, he is a member of the EORTC Pharmacokinetics and Molecular Mechanisms Group.
Professor Hilary Calvert received the Lifetime Achievement Award in the 2009 Excellence in Oncology Awards from the British Oncological Association.